Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 1
2014 2
2015 1
2016 3
2017 4
2018 1
2019 3
2020 8
2021 22
2022 12
2023 8
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
Molecular responses in decitabine- and decitabine/venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes.
Gruszczynska A, Maiti A, Miller CA, Ramakrishnan SM, Link DC, Uy GL, Petti AA, Hayes K, DiNardo CD, Ravandi F, Ley TJ, Spencer DH, Gao F, Konopleva MY, Welch JS. Gruszczynska A, et al. Among authors: konopleva my. Haematologica. 2024 Apr 11. doi: 10.3324/haematol.2022.281396. Online ahead of print. Haematologica. 2024. PMID: 38618679 Free article.
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Zhao Y, Short NJ, Kantarjian HM, Chang TC, Ghate PS PhD, Qu C, Macaron W, Jain N, Thakral B, Phillips A, Khoury JD, Garcia-Manero G, Zhang W, Fan Y, Yang H, Garris R, Nasr LF, Kriwacki R, Roberts KG, Konopleva MY, Jabbour EJ, Mullighan CG. Zhao Y, et al. Among authors: konopleva my. Blood. 2024 Mar 29:blood.2024023930. doi: 10.1182/blood.2024023930. Online ahead of print. Blood. 2024. PMID: 38551807
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.
Daver NG, Montesinos P, DeAngelo DJ, Wang ES, Papadantonakis N, Todisco E, Sweet KL, Pemmaraju N, Lane AA, Torres-Miñana L, Thompson JE, Konopleva MY, Sloss CM, Watkins K, Bedse G, Du Y, Malcolm KE, Zweidler-McKay PA, Kantarjian HM. Daver NG, et al. Among authors: konopleva my. Lancet Oncol. 2024 Mar;25(3):388-399. doi: 10.1016/S1470-2045(23)00674-5. Lancet Oncol. 2024. PMID: 38423051 Clinical Trial.
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial.
Konopleva MY, Dail M, Daver NG, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Dunshee D, Hamidi H, Ott MG, Hong WJ, Andreeff M. Konopleva MY, et al. Clin Lymphoma Myeloma Leuk. 2024 Jan 18:S2152-2650(24)00036-3. doi: 10.1016/j.clml.2024.01.007. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38378362 Free article.
Correction: Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL.
Tian Z, Shi C, Yang G, Allen JK, Shi Q, Al-Shami A, Olson JW, Smith MG, Chang Q, Kaur J, You J, Lofton TE, Gonzalez MA, Zhang Q, Zha D, Tasian SK, Jain N, Konopleva MY, Heffernan T, Molldrem JJ. Tian Z, et al. Among authors: konopleva my. Leukemia. 2024 Jan;38(1):226. doi: 10.1038/s41375-023-02090-w. Leukemia. 2024. PMID: 38036631 Free PMC article. No abstract available.
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents.
Hammond D, Loghavi S, Wang SA, Konopleva MY, Kadia TM, Daver NG, Ohanian M, Issa GC, Alvarado Y, Short NJ, Sasaki K, Pemmaraju N, Montalban-Bravo G, Lachowiez CA, Maiti A, Garcia-Manero G, Jabbour EJ, Borthakur G, Ravandi F, Takahashi K, Pierce SR, Kantarjian HM, DiNardo CD. Hammond D, et al. Among authors: konopleva my. Blood Cancer J. 2023 Sep 21;13(1):148. doi: 10.1038/s41408-023-00915-6. Blood Cancer J. 2023. PMID: 37735426 Free PMC article. No abstract available.
Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL.
Tian Z, Shi C, Yang G, Allen JK, Shi Q, Al-Shami A, Olson JW, Smith MG, Chang Q, Kaur J, You J, Lofton TE, Gonzalez MA, Zhang Q, Zha D, Tasian SK, Jain N, Konopleva MY, Heffernan T, Molldrem JJ. Tian Z, et al. Among authors: konopleva my. Leukemia. 2023 Oct;37(10):2006-2016. doi: 10.1038/s41375-023-02010-y. Epub 2023 Aug 26. Leukemia. 2023. PMID: 37634013 Free PMC article.
Interrogating bromodomain inhibitor resistance in KMT2A-rearranged leukemia through combinatorial CRISPR screens.
Wright S, Hu J, Wang H, Hyle J, Zhang Y, Du G, Konopleva MY, Kornblau SM, Djekidel MN, Rosikiewicz W, Xu B, Lu R, Yang JJ, Li C. Wright S, et al. Among authors: konopleva my. Proc Natl Acad Sci U S A. 2023 Apr 18;120(16):e2220134120. doi: 10.1073/pnas.2220134120. Epub 2023 Apr 10. Proc Natl Acad Sci U S A. 2023. PMID: 37036970 Free PMC article.
Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2).
Richard-Carpentier G, Rausch CR, Sasaki K, Hammond D, Morita K, Takahashi K, Tang G, Kanagal-Shamanna R, Bhalla K, Dinardo CD, Borthakur G, Pemmaraju N, Shpall EJ, Alousi A, Daver NG, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM, Kadia TM. Richard-Carpentier G, et al. Among authors: konopleva my. Haematologica. 2023 Sep 1;108(9):2331-2342. doi: 10.3324/haematol.2022.282030. Haematologica. 2023. PMID: 36951163 Free PMC article.
Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation.
Nguyen D, Kantarjian HM, Short NJ, Qiao W, Ning J, Cuglievan B, Daver NG, DiNardo CD, Jabbour EJ, Kadia TM, Borthakur G, Garcia-Manero G, Konopleva MY, Andreeff M, Ravandi-Kashani F, Sasaki K, Issa GC. Nguyen D, et al. Among authors: konopleva my. Cancer. 2023 Jun 15;129(12):1856-1865. doi: 10.1002/cncr.34728. Epub 2023 Mar 9. Cancer. 2023. PMID: 36892949
68 results